![]() ![]() ![]() ![]() The street high sits at C$135 from Stifel-GMP while the lowest comes in at C$54. Out of the 17 analysts, 5 have strong buy ratings and 12 have buy ratings. Trulieve Cannabis currently has 17 analysts covering the stock with an average 12-month price target of C$84.53, or a 120% upside from the current stock price. Adjusted EBITDA came in at $98 million and the company held cash of $213.6 million as of September 30th. Net income for the quarter was $18.6 million, representing their 15th consecutive profitable quarter and a positive cash flow from operations of $75.1 million. The company saw gross profits grow to $153.9 million or a gross margin of 68.7%. On November 15th, Trulieve Cannabis (CSE: TRUL) reported its third quarter results, announcing record revenues of $224.1 million, up a marginal 4.2% sequentially but up 64% year over year.
0 Comments
Leave a Reply. |